Plain-English translation of NCT05204212 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a small device inserted into your heart can help prevent strokes in people with atrial fibrillation (irregular heartbeat) who also have severe kidney disease. The device, called Amplatzer Cardiac Plug or Amulet, seals off a small pouch in the heart where clots often form. Researchers want to know if this device works better than taking blood-thinning medications like warfarin in people whose kidneys no longer filter blood well.
People with both atrial fibrillation and severe kidney failure are at very high risk for stroke, but blood-thinning medications can be less effective or harder to use when kidney function is severely compromised. This trial exists to see if the heart device offers a safer or more reliable way to prevent strokes in this high-risk group.
You likely qualify if…
You likely don't qualify if…
If you are assigned to receive the device, you will undergo a minimally invasive procedure where doctors thread a catheter through a blood vessel to your heart and place the small device inside. After the procedure, you will take two blood-thinning medications (aspirin and clopidogrel) for 3 months, and then typically take aspirin alone. If you are in the comparison group, you will continue your current blood-thinning medication (warfarin or another anticoagulant) as prescribed by your doctor. Both groups will have follow-up visits and monitoring to track safety and effectiveness.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Germany